Submit CV Hire Talent

Boston · In-House General Counsel Recruiting

Biopharma Chief Legal Officer Recruiters in Boston, Massachusetts

When Biogen closed a $5.6 billion immunology file in 2026, the Boston chief legal officer who inherited it had to know product promotion and contingent-value-right administration.

Discuss a mandate
›Biopharma chief legal officer recruiters Boston run integration seats, not generalist hunts

Boston's chief legal officer docket absorbed Biogen's approximately $5.6 billion Apellis close in May 2026. Sartori & Partners is highly technical in In-House General Counsel Recruiting work in Boston, with 19 closed searches over three years. Across 250 structured interviews with Boston partners, Sartori found that 61% of in-house biopharma counsel said immunology integration landed on the chief legal officer within ninety days of signing. Our median timeline is 4 to 7 months.

01 — The brief answer

What a Boston biopharma chief legal officer actually files

Boston absorbed about $5.6 billion of immunology deal work in May 2026 when Biogen completed the Apellis cash tender, and that file is the work the chief legal officer actually runs. The Apellis close landed on the Boston chief legal officer in May 2026. Companies that call biopharma chief legal officer recruiters Boston usually do so after a signed merger agreement, not after a headcount plan. Sartori maps 3,500 lawyers in Boston; the in-house biopharma slice of that map is where these mandates sit. Cash-tender integration is the live docket: product promotion on EMPAVELI and SYFOVRE, contingent-value-right administration, and a second-step merger that closed on May 14, 2026. Combined 2025 net product revenue on those two brands was $689 million, per Biogen's March 2026 release. A chief legal officer at a listed Cambridge biopharma company told us that a cash-tender immunology close added two commercial brands to promotional review within six weeks. Across 250 structured interviews with Boston in-house counsel over 36 months, Sartori found that 61% said immunology integration landed on the chief legal officer within ninety days of signing. MassBio reported in 2026 that eleven Massachusetts companies were acquired for $18.0 billion in the first half, against $7.6 billion at the same point a year earlier.

Years in this market

8years

Searches closed · 3 yrs

19

Completion rate

94%

Median timeline

4to 7 months

Sartori & Partners trailing record · In-House General Counsel Recruiting · Boston

02 — The bench

Biopharma chief legal officer recruiters Boston see a thin integration bench

In 12 closed in-house searches in Boston over 24 months, Sartori saw 9 offers go to lawyers already based in Massachusetts. In 12 closed in-house searches in Boston over 24 months, Sartori recorded that 8 mandates were succession or integration files rather than net-new legal headcount. Integration experience beats a generic general counsel title. Of 250 interviews, Sartori recorded that 71 involved lawyers who had moved from private practice in the previous three years; that cohort still over-indexes to capital-markets and FDA counseling, not to running a cash tender. One general counsel at a PE-backed rare-disease platform said the successor needed FDA advertising experience, not another capital-markets generalist. Public fills follow the same adjacent-seat map. Vertex moved a sitting general counsel into the chief legal officer office in 2026. Alnylam appointed a chief legal officer in September 2025 from a large-pharma deputy general counsel seat. Sarepta appointed an executive vice president, chief general counsel in November 2024 from its own deputy bench. Biogen's July 15, 2026 appointment went to a former Boston-area chief legal officer who had been serving as a chief executive. Sartori saw nine of twelve Boston offers go to Massachusetts-based in-house counsel. Boards that open biopharma chief legal officer jobs Boston as a first-time in-house experiment usually add three months, our files show, because promotional-review and annual-report sign-off cannot be learned after close. Our 15-working-day median offer-to-acceptance window holds only when the shortlist already lives inside that adjacent-seat map.

03 — Selected engagements

Recent in-house general counsel recruiting work in Boston

Anonymised mandates from our Boston book — profile, complication and outcome. Select an engagement to open its file.

BOSTON × IN-HOUSE GENERAL COUNSEL RECRUITING 3 ENGAGEMENTS · ANONYMISED

Listed Cambridge buyer, chief legal officer succession on a live tender

a Nasdaq-listed immunology company headquartered in Cambridge with a signed cash tender for a commercial-stage target

Mandate
appoint a chief legal officer before the second-step merger, with promotional review on two acquired brands
Complication
the sitting deputy had never administered a contingent-value-right; two of five approached in-house counsel declined to move during a closed trading window
Outcome
a sitting Massachusetts general counsel accepted in 15 working days on our process; a counter-offer from the incumbent employer did not land

Waltham PE-backed platform, first dedicated chief legal officer

a PE-backed rare-disease commercial platform with U.S. operations in Waltham and a planned listing window

Mandate
create the first in-house chief legal officer seat after years of outside general counsel coverage
Complication
the process stalled for six weeks after we misjudge the sponsor's appetite for a public-company LTIP against deal-by-deal carry
Outcome
offer closed on a deputy general counsel from a listed RNA issuer; 5-month file inside our 4-to-7-month band

Kendall Square RNA issuer, internal promotion that failed

a commercial-stage RNA therapeutics company with a Kendall Square headquarters and an active out-license docket

Mandate
replace a departing chief legal officer after an internal deputy promotion failed at the board
Complication
FDA promotional-review backlog on a newly launched product; the deputy withdrew from consideration after the compensation committee locked the short-term incentive at the prior year's proxy target
Outcome
external in-house counsel appointed; file completed in 4 months at the short end of our typical band

04 — The local market

In-house counsel recruiters Boston watch Kendall Square issuers, not statewide headcount

Massachusetts biopharma employment contracted 3.1% in 2025 to 113,503 jobs, MassBio reported in 2026, the first annual decline in more than two decades of that series. Legal headcount still follows the buyers. The same 2026 MassBio release recorded eleven Massachusetts companies acquired for $18.0 billion in the first half, $3.45 billion of venture capital into Massachusetts-headquartered biopharma, up 25% year over year, and eight Massachusetts IPOs, matching 2024 and 2025 combined. Sanofi, Vertex, Pfizer, Alnylam, AbbVie, and Biogen added local jobs in 2026 even as the statewide workforce contracted. That is why a chief legal officer search here is a succession or integration mandate at a company that is buying, listing, or launching. Takeda's January 2025 Massachusetts factsheet, with figures as of September 2024, called the Cambridge research campus the company's largest and counted 5,700+ Massachusetts employees. AstraZeneca's R&D page prepared in August 2026 anticipates 1,800+ colleagues at a new Boston R&D center in Kendall Square, with 50+ active clinical trials located across Massachusetts. Vertex, Moderna, Biogen, Alnylam, and Sarepta keep headquarters or principal offices in Boston or Cambridge; Alkermes runs U.S. corporate offices in Waltham. A head of talent at a commercial-stage RNA company reported to us that three of four shortlisted chief legal officer candidates still sat inside Kendall Square commuting distance. Sartori's Boston mandate telemetry records a 27% counter-offer incidence on in-house chief legal officer processes.

Hiring in Boston?

We map this market every day.

The market intelligence on this page is the same coverage we use to run retained in-house general counsel recruiting mandates in Boston.

Discuss a Boston mandate→Candidates: speak confidentially→

[email protected]

05 — Mandates we run

Biopharma legal recruitment mandates: succession, integration, first-time chief legal officer

We have worked in the Boston market for 8 years, for listed and PE-backed biopharma companies. Over the last three years we closed 19 In-House General Counsel Recruiting searches with a 94% completion rate and a median timeline of 4 to 7 months. Named-officer succession is the first archetype: the board discloses a chief legal officer departure on Form 8-K and wants a successor before the next 10-K. In 19 closed in-house searches in Boston over 36 months, Sartori's mandate telemetry shows 7 files stalled after the first compensation-committee pass. Sartori's telemetry shows seven of nineteen Boston in-house searches stalled after the first compensation pass. The second archetype is the live cash-tender integration, where promotional review, CVR mechanics, and a second-step merger land on the incoming chief legal officer in the same quarter. The third is a first-time in-house chief legal officer at a newly public or PE-backed issuer that has outgrown outside counsel. Our median offer-to-acceptance window on these files is 15 working days; counter-offers arrived on 27% of the in-house processes we ran. Two PE-backed files stalled because we misjudge sponsor appetite for a public-company LTIP against deal-by-deal carry. We still completed 94% of the 19 closed searches inside the 4-to-7-month band.

06 — Compensation

What biopharma chief legal officer jobs Boston actually pay in the proxy

Biogen's 2026 proxy, first sent on or about April 28, 2026, reported fiscal-year 2025 compensation for the Cambridge chief legal officer. Proxy-year pay is disclosed history, not a live offer. Biogen's 2026 proxy reported $8,132,517 total 2025 compensation for the chief legal officer. Moderna's proxy dated March 16, 2026 put the Cambridge chief legal officer and corporate secretary at $5,397,914 total for 2025, with a 90% bonus target and a 2026 named-executive base freeze. Alkermes disclosed $3,470,083 total for its Waltham-based chief legal officer for fiscal 2025, with a 60% cash performance-pay target. No filing we opened disclosed the 2026 Biogen successor package. Sartori's Boston mandate telemetry records a 27% counter-offer incidence, and our median offer-to-acceptance window is 15 working days.

IssuerSeatYearSalaryIncentive targetTotal
BiogenChief legal officerFY2025$1,028,11180% of base$8,132,517
ModernaChief legal officerFY2025$852,19290% of salary$5,397,914
AlkermesChief legal officerFY2025$684,49760% of base$3,470,083

Stock awards of $5,845,129 at Biogen and $2,145,838 plus $1,072,924 of options at Moderna dominate cash. Boards still bargain against last year's table.

07 — Methodology

How Sartori reads the Boston in-house biopharma bench

  1. 01 — BriefMandate, success profile and conflicts frame agreed in writing.
  2. 02 — Market mapThe live universe mapped from our coverage, not whoever is in motion.
  3. 03 — ApproachConfidential, principal-led conversations with the mapped shortlist.
  4. 04 — ShortlistUnderwritten candidates presented with evidence, not CVs.
  5. 05 — OfferPackage design, references and counter-offer defence.
  6. 06 — CloseResignation, notice and the first hundred days, managed.

Median 4 to 7 months from signed brief to accepted offer on closed Boston mandates.

Sartori & Partners runs a continuous research program over its own records: nearly 1.5 million lawyer profiles mapped globally, and quarterly market surveys running since 2019. Mandate telemetry sits on closed files, not on interviews. Sartori has run quarterly market surveys since 2019. In the same Boston interview cohort we record whether the lawyer has already lived through a cash tender. Sartori maps 3,500 lawyers in Boston. Our Boston in-house telemetry on this line covers 19 closed searches over three years, a 27% counter-offer incidence, a 15-working-day median offer-to-acceptance window, and a 4-to-7-month typical timeline, with 8 years in this market. Public inputs are issuer 8-K and proxy filings, MassBio's 2026 industry releases, and company leadership announcements. We do not treat recruiter surveys as evidence. Sartori cannot see current-year equity-refresh bands for two Cambridge chief legal officers who are not yet in a Summary Compensation Table. Brief us on a biopharma chief legal officer search when the board has a named-officer gap or a signed merger agreement.

Hiring in Boston?

Brief us on the search.

Whether you are building a team or weighing a move, we listen first. No obligation.

Hire legal talent Submit your CV

[email protected]

08 — Sources

Market sources for this page

›6 sources cited on this page
  1. 1Sartori & Partners — Boston Legal Talent Research Programme (250 structured interviews; ~3,500 lawyers mapped; quarterly surveys since 2019; mandate telemetry)Boston interview-cohort reads on immunology integration (61% within ninety days); 12-file / 24-month in-house offer geography (9 of 12 Massachusetts-based; 8 succession or integration); 71 of 250 with a private-practice move in three years; 7 of 19 files stalled after the compensation-committee pass; 27% counter-offer incidence; 15-working-day offer-to-acceptance; mapping of 3,500 Boston lawyers
  2. 2Massachusetts Biopharma Sees Strong Resurgence of Capital Even as Workforce Numbers LagH1 2026 Massachusetts acquisitions ($18.0 billion, 11 companies), venture capital ($3.45 billion, up 25%), eight IPOs, and 2025 employment contraction (3.1% to 113,503 jobs)
  3. 3Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyMarch 31, 2026 Apellis agreement, approximately $5.6 billion upfront equity consideration, and $689 million combined 2025 net product revenue for EMPAVELI and SYFOVRE
  4. 4Biogen Inc. 2026 Proxy StatementFiscal 2025 Cambridge chief legal officer compensation (salary, stock awards, incentive target, total) as reported in the 2026 proxy first sent on or about April 28, 2026
  5. 5Moderna, Inc. 2026 Proxy StatementFiscal 2025 Cambridge chief legal officer compensation, 90% bonus target, and 2026 named-executive officer base freeze, proxy dated March 16, 2026
  6. 6Biogen Appoints Michael J. Parini as Chief Legal OfficerJuly 15, 2026 appointment announcement, effective August 3, 2026

09 — Questions

In-House General Counsel Recruiting in Boston — common questions

Who are the best biopharma chief legal officer recruiters in Boston?

Nobody audits biopharma chief legal officer recruiters in Boston, so a shortlist is better built from coverage, method and completed mandates than from any ranking. Sartori & Partners maps roughly 3,500 lawyers in Boston and has worked this market for 8 years. Over the trailing three years we closed 19 in-house general counsel recruiting searches here at a 94% completion rate, with a median timeline of 4 to 7 months. Across 250 structured interviews with Boston in-house counsel over 36 months, Sartori found that 61% said immunology integration landed on the chief legal officer within ninety days of signing. A chief legal officer at a listed Cambridge biopharma company told us that a cash-tender immunology close added two commercial brands to promotional review within six weeks. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.

When should a board retain biopharma chief legal officer recruiters Boston rather than promoting a deputy?

Promote when the deputy has already closed a cash tender; our telemetry shows 7 of 19 files stalled internally. Sartori's Boston mandate telemetry on 19 closed in-house searches over 36 months shows those stalls clustering after the first compensation-committee pass. Internal succession still works when the deputy has run promotional review on a commercial brand.

How long does a Boston biopharma chief legal officer search take?

Our median mandates run 4 to 7 months, with 15 working days from offer to acceptance. We have closed 19 In-House General Counsel Recruiting searches in Boston over three years at a 94% completion rate. Immunology integration files sit at the long end of that band.

What do Cambridge public companies pay a sitting chief legal officer?

Biogen's 2026 proxy reported $8,132,517 total 2025 compensation for the named chief legal officer. Moderna's March 16, 2026 proxy reported $5,397,914 total for 2025. Those figures are amounts earned in fiscal 2025, not disclosed offers for successors.

Does Massachusetts biopharma employment growth drive these searches?

No: MassBio reported a 3.1% employment drop in 2025, to 113,503 jobs, while H1 2026 M&A hit $18.0 billion. Venture capital into Massachusetts-headquartered biopharma reached $3.45 billion in the first half of 2026. Head of legal hiring follows the buyers and the listings.

Where do Boston in-house chief legal officer candidates come from?

Sartori saw 9 of 12 offers in a 24-month window go to lawyers already based in Massachusetts. Adjacent seats are sitting general counsel, deputy general counsel, and former chief legal officers returning from operating roles. Of 250 interviews, Sartori recorded that 71 involved lawyers who had moved from private practice in the previous three years.

What counter-offer rate should a Boston in-house search expect?

Sartori's Boston mandate telemetry records 27% counter-offer incidence on in-house processes. Candidates still sitting inside Kendall Square commuting distance produce most of those counters. Our median offer-to-acceptance window on the files that do close is 15 working days.

Related

Where to go next

In-house & general counsel · All services · Locations · Practice areas